Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
Molecular markers in circulating tumour cells from metastatic colorectal cancer patients.
复制标题
DOI：
10.1111/j.1582-4934.2010.01117.x
复制
发表时间：
2010-08
影响因子：
5.3
通讯作者：
Cortesi E
中科院分区：
文献类型：
--
作者：
Gazzaniga P;Gradilone A;Petracca A;Nicolazzo C;Raimondi C;Iacovelli R;Naso G;Cortesi E
转移性癌症患者的预后仍然在很大程度上受到治疗失败的影响，主要是由于耐药性。化疗可能错过循环肿瘤细胞（CTC），特别是更具侵略性的干细胞样CTC亚群，其特征是多药耐药性的假设，最近已经提出。我们研究了来自接受奥沙利铂（L-OHP）和5-氟尿嘧啶（5-FU）方案治疗的转移性结直肠癌患者的CTC中耐药和干性标志物的预后价值。入组了40例转移性结直肠癌患者。从外周血中分离CTC，并分析乙醛脱氢酶1（ALDH 1）、CD 44、CD 133（用作干性标志物）、多药耐药相关蛋白5（MRP 5用作对5-FU和L-OHP的耐药标志物）和存活素（用作凋亡耐药标志物）的表达。在27/40（67%）例患者中发现CTC。CTCs中CD 44和CD 133的表达与患者的预后之间没有相关性，而在ALDH 1、Survivin和MRP 5表达阳性的CTCs患者中，无进展生存期在统计学上显著缩短。这些结果支持了这样的观点，即分离存活素和MRP 5 + CTC可能有助于选择对基于标准5-FU和L-OHP的化疗耐药的转移性结直肠癌患者，对于这些患者，替代方案可能是合适的。
The prognosis of metastatic cancer patients is still largely affected by treatment failure, mainly due to drug resistance. The hypothesis that chemotherapy might miss circulating tumour cells (CTCs) and particularly a subpopulation of more aggressive, stem-like CTCs, characterized by multidrug resistance, has been recently raised. We investigated the prognostic value of drug resistance and stemness markers in CTCs from metastatic colorectal cancer patients treated with oxaliplatin (L-OHP) and 5-fluoruracil (5-FU) based regimens. Forty patients with metastatic colorectal cancer were enrolled. CTCs were isolated from peripheral blood and analysed for the expression of aldheyde dehydrogenase 1 (ALDH1), CD44, CD133 (used as markers of stemness), multidrug resistance related protein 5 (MRP5 used as marker of resistance to 5-FU and L-OHP) and survivin (used as a marker of apoptosis resistance). CTCs were found in 27/40 (67%) patients. No correlation was found between the expression of either CD44 and CD133 in CTCs and the outcome of patients, while a statistically significant shorter progression-free survival was found in patients with CTCs positive for the expression of ALDH1, survivin and MRP5. These results support the idea that isolating survivin and MRP5+ CTCs may help in the selection of metastatic colorectal cancer patients resistant to standard 5-FU and L-OHP based chemotherapy, for which alternative regimens may be appropriate.
登录
查看更多内容
影响因子：
13.6
作者：
Huang EH;Wicha MS
通讯作者：
Wicha MS
影响因子：
6.4
作者：
Gazzaniga, Paola;Naso, Giuseppe;Cristofanilli, Massimo
通讯作者：
Cristofanilli, Massimo
影响因子：
12.8
作者：
Nakagawa, Yasunori;Abe, Shinya;Kitagawa, Masanobu
通讯作者：
Kitagawa, Masanobu
影响因子：
9.7
作者：
Theodoropoulos, Panayiotis A.;Polioudaki, Hara;Georgoulias, Vassilis
通讯作者：
Georgoulias, Vassilis
影响因子：
4.3
作者：
Negin, Benjamin P.;Cohen, Steven J.
通讯作者：
Cohen, Steven J.